22. January 2021
Transglutaminase-Newsletter | January 2021
Dear Transglutaminase researchers,
On January 20th 2021, Technoclone (Vienna, Austria) and Zedira published the second joint paper entitled "Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity".
The paper was published in the International Journal of Molecular Sciences as part of the Special Issue Fibrinogen/Fibrin, Factor XIII and Fibrinolysis in Diseases. The accurate, rapid, and precise assay is meant to improve routine diagnostics and therefore should help patients, physicians, and researchers.
At Zedira, we are scientists at heart. Cutting edge science and technology are mandatory for entrepreneurial success in the biotech business. Besides tissue transglutaminase, our research focused on coagulation factor XIII for already about two decades by now.
Our proprietary compound ZED3197 showed the proof-of-principle of “safe” anticoagulation therapy. Specific inhibition of FXIIIa allows unprecedented intervention in the coagulation cascade (published in Journal of Thrombosis and Haemostasis as Open access paper).
We are happy to share with you our exclusive products to support your esteemed research & development. Please find bellow a collection of our most important FXIII related tools.
Assays and Substrates
Inhibitors
Clinical Validation of an Automated Fluorogenic FXIII Activity Assay
Transglutaminase-Newsletter | January 2021Dear Transglutaminase researchers,
On January 20th 2021, Technoclone (Vienna, Austria) and Zedira published the second joint paper entitled "Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity".
The paper was published in the International Journal of Molecular Sciences as part of the Special Issue Fibrinogen/Fibrin, Factor XIII and Fibrinolysis in Diseases. The accurate, rapid, and precise assay is meant to improve routine diagnostics and therefore should help patients, physicians, and researchers.
At Zedira, we are scientists at heart. Cutting edge science and technology are mandatory for entrepreneurial success in the biotech business. Besides tissue transglutaminase, our research focused on coagulation factor XIII for already about two decades by now.
Our proprietary compound ZED3197 showed the proof-of-principle of “safe” anticoagulation therapy. Specific inhibition of FXIIIa allows unprecedented intervention in the coagulation cascade (published in Journal of Thrombosis and Haemostasis as Open access paper).
We are happy to share with you our exclusive products to support your esteemed research & development. Please find bellow a collection of our most important FXIII related tools.
FXIII
| Art. No. | Name | Unit | Price |
| T027 | Human blood coagulation Factor XIII-A2, recombinant (hFXIII, A subunit, recombinantly produced in insect cells) | 200 µg | 370 € |
| T070 | Human Factor XIIIa, Thrombin activated (hFXIIIa, recombinantly produced in insect cells) | 200 µg | 520 € |
| T050 | Human blood coagulation Factor XIII B subunit (hFXIII B, F13B, recombinantly produced in insect cells) | 200 µg | 370 € |
Assays and Substrates
| Art. No. | Name | Unit | Price |
| A101 | FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH | 10 mg | 520 € |
| F001 | FXIII-Assay Kit (ready to use, contains A101 and thrombin) | 1 Kit | 575 € |
Inhibitors
| Art. No. | Name | Unit | Price |
| T101 | 1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride | 10 mg | 480 € |
| A108 | Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH (Synonym ZED1301, site specific irreversible inhibitor of FXIII) | 5 mg | 480 € |
NEW
| Art. No. | Name | Unit | Price |
| T222 | Human Alpha Thrombin, recombinant | 100 NIH Units | 185 € |
Antibodies
| Art. No. | Name | Unit | Price |
| A016 | Polyclonal antibody to human factor XIII (A-subunit) | 500 µg | 365 € |
| A032 | FITC-labeled polyclonal antibody to human factor XIII (A-subunit) | 200 µg | 395 € |
| A074 | Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09) | 200 µg | 365 € |
| A077 | FITC-labeled polyclonal antibody to human factor XIII (B-subunit) | 200 µg | 365 € |
| A076 | "DD-XLink-mab" Monoclonal antibody against crosslinked fibrin ("D-dimer") | 100 µg | 365 € |
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation